Goodwill and Intangible Assets, Net - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) Reporting_Unit	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Finite Lived Intangible Assets [Line Items]
Weighted-average useful life of intangible assets		6 years 6 months 10 days
Amortization expense of intangible assets		$ 1,900,000	$ 1,800,000	$ 1,900,000
Intangible assets Impairments		$ 1,740,000
Number of reporting units | Reporting_Unit		2
Goodwill impairment	$ 67,700,000	$ 67,679,000	0	0
Research and Development Expenses
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments				$ 200,000
CDE IPR&D
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments		0	$ 0
Kurr In- Process Research and Development
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments		0
Global Supply Chain Platform
Finite Lived Intangible Assets [Line Items]
Goodwill impairment	26,600,000	26,638,000
Oncology Innovation Platform
Finite Lived Intangible Assets [Line Items]
Goodwill impairment	41,100,000	41,041,000
Licensing Agreements | Hanmi Pharmaceuticals Co. Ltd.
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired		$ 400,000
Acquired finite-lived intangible assets, amortization period		12 years 9 months
Licensing Agreements | Gland Pharma Ltd
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired		$ 3,800,000
Acquired finite-lived intangible assets, amortization period		5 years
Licensing Agreements | MAIA Pharmaceuticals, Inc
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired		$ 4,000,000.0
Acquired finite-lived intangible assets, amortization period		7 years
Licensing Agreements | Ingenus Pharmaceuticals, LLC
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired		$ 3,000,000.0
Licenses of Other Specialty Products | Ingenus Pharmaceuticals, LLC
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired		$ 1,500,000
Customer List | Maximum
Finite Lived Intangible Assets [Line Items]
Goodwill impairment	100,000
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period		6 years
Polymed Technology
Finite Lived Intangible Assets [Line Items]
Goodwill impairment	$ 1,700,000
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period		12 years
Licensing Agreements Amortized Over a Period of 5 years | Ingenus Pharmaceuticals, LLC
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period		5 years
Licensing Agreements Amortized Over a Period of 3 years | Ingenus Pharmaceuticals, LLC
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period		3 years